Daniel Wayne Simon

US Patent:

6562344, May 13, 2003

Filed:

May 9, 1995

Appl. No.:

08/437884

Inventors:

Jonathan Stamler - Boston MA
Joseph Loscalzo - Dedham MA
Daniel Simon - Waban MA
David Singel - Arlington MA

Assignee:

Brigham and Womens Hospital - Boston MA

International Classification:

A61K 3940

US Classification:

4241811, 4241301, 5303911, 5303917

Abstract:

Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body. The invention also relates to the nitrosylation of oxygen, carbon and nitrogen moieties present on proteins and amino acids, and the use thereof to achieve the above physiological effects.

US Patent:

7157500, Jan 2, 2007

Filed:

Aug 13, 2002

Appl. No.:

10/216865

Inventors:

Jonathan Stamler - Boston MA, US
Joseph Loscalzo - Dedham MA, US
Daniel Simon - Waban MA, US
David Singel - Arlington MA, US

Assignee:

Brigham and Women's Hospital - Boston MA

International Classification:

A01N 33/18

US Classification:

514742, 514740

Abstract:

Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body. The invention also relates to the nitrosylation of oxygen, carbon and nitrogen moieties present on proteins and amino acids, and the use thereof to achieve the above physiological effects.

US Patent:

20020006401, Jan 17, 2002

Filed:

Feb 7, 2001

Appl. No.:

09/776533

Inventors:

Campbell Rogers - Westwood MA, US
Elazer Edelman - Brookline MA, US
Daniel Simon - Waban MA, US

Assignee:

Massachusetts Institute of Technology

International Classification:

A61K039/395

US Classification:

424/130100

Abstract:

Compounds that specifically inhibit or reduce leukocyte adhesion or function are useful to enhance vascular healing and lessen restenosis of blood vessels after revascularization, via angioplasty or bypass surgery, of diseased coronary, peripheral and cerebral arteries, and lessen stenosis or restenosis of surgically-placed bypass grafts and transplanted organs. Examples of these compounds are those which block cell surface integrins or their ligands, for example, the leukocyte integrin Mac-1 (CD11b/CD18, M2). As demonstrated by the examples, both superficial and deep injury was significantly reduced with treatment using an antibody to Mac-1 compared to both saline controls and IgG controls. After balloon angioplasty (superficial injury) neointimal area was reduced nearly 70%. The ratio of intimal:medial area, which is customarily used in balloon-injured experimental arteries to normalize for small normal variations in arterial size from one animal to another, was reduced over 75%. After endovascular stent implantation (deep injury) neointimal area was reduced nearly 40%. Extrapolated to humans, this reduction in the intimal thickening would reduce restenosis from occurring in approximately 30% of patients to less than 10% of patients.

US Patent:

20020127763, Sep 12, 2002

Filed:

Dec 28, 2000

Appl. No.:

09/752798

Inventors:

Mohamed Arafa - Chandler AR, US
Weimin Han - Portland OR, US
Alan Myers - Portland OR, US
Daniel Simon - Hillsboro OR, US

International Classification:

H01L021/00

US Classification:

438/076000

Abstract:

L-shaped spacers for use adjacent to the vertical sidewalls of gate electrodes in the manufacture of MOS integrated circuits are described along with methods of fabricating such structures that do not require any additional cost compared to conventional manufacturing processes. A spacer is formed as a tri-layer of silicon oxide/silicon nitride/silicon oxide deposited in- situ at low temperature using a conventional furnace and a bis(tertiarybutylamino) silane chemistry deposition. The spacer has the same performance as a conventional spacer during deep source/drain (S/D) implants. Prior to a cleaning operation which precedes silicidation, the top oxide layer is removed leading to improved gap-fill characteristics. The upper oxide may to removed before deep S/D implantation to further achieve reduction of series resistance.

US Patent:

58638903, Jan 26, 1999

Filed:

Aug 6, 1997

Appl. No.:

8/907217

Inventors:

Jonathan Stamler - Boston MA
Joseph Loscalzo - Dedham MA
Daniel Simon - Waban MA
David Singel - Arlington MA

Assignee:

Brigham and Women's Hospital - Boston MA

International Classification:

A61K 3802
A61K 3817
C07K 1113
C07K 1447

US Classification:

514 2

Abstract:

Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body. The invention also relates to the nitrosylation of oxygen, carbon and nitrogen moieties present on proteins and amino acids, and the use thereof to achieve the above physiological effects.

US Patent:

55938760, Jan 14, 1997

Filed:

Aug 9, 1994

Appl. No.:

8/287830

Inventors:

Jonathan Stamler - Boston MA
Joseph Loscalzo - Dedham MA
Daniel Simon - Waban MA
David Singel - Arlington MA

Assignee:

Brigham and Women's Hospital - Boston MA

International Classification:

C12N 996
C12N 972
C12N 970
C12N 948

US Classification:

435188

Abstract:

Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and S-nitroso-immunoglobulin. The invention also relates to therapeutic use of S-nitroso-protein compounds for regulating protein function, cellular metabolism and effecting vasodilation, platelet inhibition, relaxation of non-vascular smooth muscle, and increasing blood oxygen transport by hemoglobin and myoglobin. The compounds are also used to deliver nitric oxide in its most bioactive form in order to achieve the effects described above, or for in vitro nitrosylation of molecules present in the body. The invention also relates to the nitrosylation of oxygen, carbon and nitrogen moieties present on proteins and amino acids, and the use thereof to achieve the above physiological effects.

US Patent:

56483937, Jul 15, 1997

Filed:

Aug 29, 1994

Appl. No.:

8/297698

Inventors:

Jonathan Stamler - Boston MA
Joseph Loscalzo - Dedham MA
Adam Slivka - Randolph MA
Daniel Simon - Waban MA
Robert Brown - Natick MA
Jeffrey Drazen - Winchester MA

Assignee:

Brigham & Women's Hospital - Boston MA

International Classification:

A61K 31195
A61K 3113

US Classification:

514562

Abstract:

Methods of relaxing corpus cavernosum smooth muscle, treating disease states responsive to prevention or relaxation of undesirable contractions of corpus cavernosum smooth muscle and of treating male impotence by administering an S-nitrosothiol such as a low molecular weight S-nitrosothiol, S-nitroso-ACE-inhibitor or S-nitroso-protein.

US Patent:

20170053998, Feb 23, 2017

Filed:

Mar 24, 2014

Appl. No.:

15/118838

Inventors:

- Santa Clara CA, US
Daniel A. SIMON - Hillsboro OR, US
Kelin J. KUHN - Aloha OR, US
Curtis W. WARD - Hillsboro OR, US

International Classification:

H01L 29/66
H01L 29/423
H01L 29/786
H01L 29/06

Abstract:

A nanowire device having a plurality of internal spacers and a method for forming said internal spacers are disclosed. In an embodiment, a semiconductor device comprises a nanowire stack disposed above a substrate, the nanowire stack having a plurality of vertically-stacked nanowires, a gate structure wrapped around each of the plurality of nanowires, defining a channel region of the device, the gate structure having gate sidewalls, a pair of source/drain regions on opposite sides of the channel region; and an internal spacer on a portion of the gate sidewall between two adjacent nanowires, internal to the nanowire stack. In an embodiment, the internal spacers are formed by depositing photo-definable spacer material in dimples etched adjacent to the channel region. Photo-definable material remains in the dimples by altering the etch characteristics of material outside of the dimples and selectively removing altered photo-definable material outside of the dimples.